PixCell Medical Technologies. (3/14/18). "Press Release: PixCell Medical Awarded 2.5 Million Euros Grant by the European Commission to Support Commercialization of its Disruptive Blood Testing Technology". Yokneam.

	Region	EU (European Union)
	Organisation	PixCell Medical Technologies (IL)
	Organisation 2	European Commission (EC)
	Group	EU (govt)
	Product	HemoScreen portable blood analyzer
	Product 2	point-of-care diagnostic device
	Index term	PixCell Medical–EU (govt): grant, 201803 Horizon 2020 SME €2.5m grant for commerialization of HemoScreen blood analyzer

PixCell announced today that it had been awarded €2.5 million by the European commission to accelerate commercialization of its product the HemoScreen.

The two-year award was granted through Horizon 2020's SME instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare.

According to the company the funding will serve to further test its product in different clinical settings and demonstrate its clinical and economic benefits as well as support the scaling up of its production.

The HemoScreen is a portable easy-to-use blood analyzer which can be operated by anyone. It performs the most common blood test: Complete Blood Count within 5 minutes enabling physicians to diagnose and treat their patients during a single visit. The HemoScreen is supposed to significantly enhance workflow efficiency in settings such as ER, Oncology and pediatric departments as well as improve patient compliance and satisfaction.

The technology is based on an innovative Lab-On-a-Cartridge concept which executes a complex lab procedure on a simple disposable without user intervention. A new physical phenomenon called Viscoelastic Focusing, machine vision and AI harnessed together yield lab-accurate results in a miniature apparatus.

The HemoScreen performance has been comprehensively validated in 3 clinical studies in the US in which operators without any training have tested thousands of blood samples covering a variety of blood disorders showing excellent correlation to high-end lab analyzers. The product is CE marked and expected to be FDA cleared during 2018.

The company says it is developing additional assays based on the same technology which will be performed on the same analyzer using different cartridges. These assays will enable physicians to make more substantiated decisions such as prescribing antibiotics and referral to the ER at the point of care.

Company website: http://www.pixcell-medical.com

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]